Study examines access to Rxs

January 2013
Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p72
Trade Publication
The article informs about the Access to Medicine Index, an independent initiative exploring efforts of pharmaceutical companies in developing countries that lack reliable access to medicines, in which GlaxoSmithKline PLC secured first ranking for 2012.


Related Articles

  • Drug patent plan gets mixed reviews. Butler, Declan // Nature;2/26/2009, Vol. 457 Issue 7233, p1 

    The article discusses the reaction to U.S. pharmaceutical company GlaxoSmithKline's (GSK) decision to share some of its patents to increase research efforts into neglected diseases and make its drugs available to the poorest countries through cheaper prices. Topics include an explanation of a...

  • Say One Thing, Do Another.  // Pharmaceutical Executive;Aug2001, Vol. 21 Issue 8, p26 

    Presents the issues concerning access to medicine in developing countries which were discussed in the annual meeting of the European Federation of Pharmaceutical Industries Association in 2001. Factors which bar access to medicines; Contribution of GlaxoSmithKline company in the improvement of...

  • Big Pharma has a heart after all.  // New Scientist;2/21/2009, Vol. 201 Issue 2696, p6 

    This article states that GlaxoSmithKline (GSK) has announced a host of measures to make medicines more available to the world's poor, raising hopes that its rivals will do the same. In a speech at Harvard Medical School on 13 February, the chairman of GSK, Andrew Witty, declared that his company...

  • GlaxoSmithKline tops the list of companies making drugs accessible to poor countries. Jack, Andrew // BMJ: British Medical Journal (International Edition);6/21/2008, Vol. 336 Issue 7658, p1396 

    The author reports on actions taken by drug manufacturers in Europe in assisting poor countries throughout the world in purchasing medicine. Actions taken by several companies in assisting countries in the developing world are mentioned, including GlaxoSmithKline. Comparisons are made between...

  • Charity calls for pooling of patents for newer HIV drugs. Mayor, Susan // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/10/2009, Vol. 339 Issue 7725, p826 

    The article deals with the appeal of the international medical aid organization Médecins Sans Frontières (MSF) to pharmaceutical companies like Abbott Laboratories, GlaxoSmithKline and Pfizer to pool their patents on newer HIV drugs and to market them in developing countries in 2009. An...

  • Big Pharma and AIDS: Act II. Weissman, Robert // Multinational Monitor;Mar/Apr2007, Vol. 28 Issue 2, p11 

    The article reports on the development of HIV/AIDS treatment by pharmaceutical companies worldwide. it reports that the gains in treatment provision are threatened by the high cost of new AIDS drugs. BY 2004, Medecins San Frontieres (MSF)/Doctors without Borders, had already warned about the...

  • Big Pharma's Manufacturing Blueprint for the Future. Van Arnum, Patricia // Pharmaceutical Technology;Aug2011, Vol. 35 Issue 8, p40 

    The article offers information on the manufacturing activities of several pharmaceutical companies worldwide from 2010 to 2011. It mentions the restructuring of manufacturing network by Pfizer Inc. and the investment strategy in emerging markets by GlaxoSmithKline (GSK). A chart is also...

  • Developing countries can contribute to global health innovation. Chakma, Justin; Chakma, Hiroshi // Nature Medicine;Feb2013, Vol. 19 Issue 2, p129 

    A letter to the editor is presented in response to an article related to the contribution of the pharmaceutical industry in developing countries towards global health innovation which was published in the 2012 issue of the periodical.

  • GlaxoSmithKline to make investments in health infrastructure within developing nations. Vogel, Lauren // CMAJ: Canadian Medical Association Journal;7/12/2011, Vol. 183 Issue 10, pE649 

    The article reports on the plans pharmaceutical company GlaxoSmithKline to reinvest one-fifth of its profits from drug sales for health infrastructure within the developing nations.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics